Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition

Oncogene

Volumn 22, Issue 39, 2003, Pages 8021-8030

  Totzke, Gudrun ^a   Schulze Osthoff, Klaus ^a   Jänicke, Reiner U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; COX 2; Death receptor; Nimesulide; NS 398

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN E2; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SENSITIZATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0345549483     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206837     Document Type: Article

References (58)

1. Callejas NA, Casado M, Bosca L and Martin-Sanz P. (2000). Hepatology, 35, 341-348.
2. Cao Y and Prescott SM. (2002). J. Cell. Physiol., 190, 279-286.
3. Chang YW, Jakobi R, McGinty A, Foschi M, Dunn MJ and Sorokin A. (2000). Mol Cell. Biol., 20, 8571-8579.
4. Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K. (2001). Leukemia, 15, 1022-1032.
5. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB and Subbaramaiah K. (2001). Lancet Oncol., 2, 544-551.
6. Davies NM, McLachlan AJ, Day RO and Williams KM. (2000). Clin. Pharmacokinet., 38, 225-242.
7. Dempke W, Rie C, Grothey A and Schmoll HJ. (2001). J. Cancer Res. Clin. Oncol., 127, 411-417.
8. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B and Martinou JC. (2001). Mol. Cell, 8, 601-611.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN. (1994). Gastroenterology, 107, 1183-1188.
10. Elder DJ, Halton DE, Hague A and Paraskeva C. (1997). Clin. Cancer Res., 3, 1679-1683.
11. Elder DJ, Halton DE, Playle LC and Paraskeva C. (2002). Int. J. Cancer, 99, 323-327.
12. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K and Wesselborg S. (2000). Oncogene, 19, 4563-4573.
13. Grösch S, Tegeder I, Niederberger E, Bräutigam L and Geisslinger G. (2001). FASEB J., 15, 2742-2744.
14. Gupta RA and DuBois RN. (2000). Ann. N. Y. Acad. Sci., 10, 196-204.
15. He Q, Luo X, Huang Y and Sheikh MS. (2002). Oncogene, 21, 6032-6040.
16. Held J and Schulze-Osthoff K. (2001). Drug Resist. Update, 4, 243-252.
17. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M and Takahashi T. (2000). Clin. Cancer Res., 6, 2006-2011.
18. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T. (1998). Cancer Res., 58, 3761-3764.
19. Hsi LC, Baek SJ and Eling TE. (2000). Exp. Cell Res., 256, 563-570.
20. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS. (2000). J. Biol. Chem., 275, 11397-11403.
21. Huang Y, He Q, Hillman MJ, Rong R and Sheikh MS. (2001). Cancer Res., 61, 6918-6924.
22. Jänicke RU, Lee FHH and Porter AG. (1994). Mol. Cell. Biol., 14, 5661-5670.
23. Jänicke RU, Lin XY, Lee FH and Porter AG. (1996). Mol. Cell. Biol., 16, 5245-5253.
24. Jänicke RU, Sprengart ML, Wati MR and Porter AG. (1998). J. Biol. Chem., 273, 9357-9360.
25. Jendrossek V, Handrick R and Belka C. (2003). FASEB J. in press.
26. Jiang XH, Lam SK, Lin MCM, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB and Wong BCY. (2002). Oncogene, 21, 6113-6122.
27. Karin M and Lin A. (2002). Nat. Immunol., 3, 221-227.
28. Ko Y, Totzke G, Schiermeyer B, Zeitler H, Schmitz U, Vetter H and Sachinidis A. (1995). Mol. Cell. Probes, 9, 215-222.
29. Lin MT, Lee RC, Yang PC, Ho FM and Kuo ML. (2001). J. Biol. Chem., 276, 48997-49002.
30. Liu XH, Yao S, Kirschenbaum A and Levine AC. (1998). Cancer Res., 58, 4245-4249.
31. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K, (2000). Cancer Res., 60, 1306-1311.
32. McGinty A, Chang YWE, Sorokin A, Bokemeyer D and Dunn MJ. (2000). J. Biol. Chem., 275, 12095-12101.
33. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores GJ. (2002). Hepatology, 35, 552-559.
34. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM. (1996). Cell, 87, 803-809.
35. Porter AG and Jänicke RU. (1999). Cell Death Differ., 6, 99-104.
36. Ravi R and Bedi A. (2002). Cancer Res., 62, 4180-4185.
37. Ricchi P, Di Matola T, Ruggiero G, Zanzi D, Apicella A, di Palma A, Pensabene M, Pignata S, Zarrilli R and Acquaviva AM. (2002). Br. J. Cancer, 86, 1501-1509.
38. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P and Härkönen M. (1997). Cancer Res., 57, 1276-1280.
39. Ruzzene M, Penzo D and Pinna LA. (2002). Biochem. J., 364, 41-47.
40. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME. (1998). Eur. J. Biochem., 254, 439-459.
41. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM and Lippman SM. (2000). Cancer Res., 60, 6846-6850.
42. Smith M, Hawcroft G and Hull MA. (2000). Eur. J. Cancer, 36, 664-674.
43. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK and Chen CS. (2002). J. Natl. Cancer Inst., 94, 585-591.
44. Souza RF, Shewmake K, Beer DG, Cryer B and Spechler SJ. (2000). Cancer Res., 60, 5767-5772.
45. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B. (2000). N. Engl. J. Med., 342, 1946-1952.
46. Stier S, Totzke G, Grünewald E, Neuhaus T, Fronhoffs S, Sachinidis A, Vetter H, Schulze-Osthoff K and Ko Y. (2000). FEBS Lett., 467, 299-304.
47. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB and Dannenberg AJ. (1996). Cancer Res., 56, 4424-4429.
48. Taketo MM. (1998). J. Natl. Cancer Inst., 90, 1609-1620.
49. Tang W, Sun YJ, Half E, Kuo MT and Sinicrope F. (2002). Cancer Res., 62, 4903-4908.
50. Tegeder I, Pfeilschifter J and Geisslinger G. (2001). FASEB J., 15, 2057-2072.
51. Thun MJ, Henley SJ and Patrono C. (2002). J. Natl. Cancer Inst., 94, 252-266.
52. Tucker ON, Dannenberg AJ, Yang FK, Zhang F, Teng LS, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT and Fahey TJ. (1999). Cancer Res., 59, 987-990.
53. Walczak H and Krammer PH. (2000). Exp. Cell Res., 256, 58-66.
54. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J. (2002). Cancer Res., 62, 2029-2033.
55. Wesselborg S, Engels IH, Rossmann E, Los M and Schulze-Osthoff K. (1999). Blood, 93, 3053-3063.
56. Wong BC, Jiang XhX, Fan XM, Lin MC, Jiang SH, Lam SK and Kung HF. (2003). Oncogene, 22, 1189-1197.
57. Zhang X, Morham SG, Langenbach R and Young DA. (1999). J. Exp. Med., 190, 451-459.
58. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K. (1999). Cancer Res., 59, 198-204.